Factors Associated with the Need for Insulin as a Complementary Treatment to Metformin in Gestational Diabetes Mellitus

Detalhes bibliográficos
Autor(a) principal: Souza,Matheus Leite Ramos de
Data de Publicação: 2019
Outros Autores: Silva,Rodrigo Ribeiro e, Silva,Thiago Ribeiro e, Oliveira,Larissa Cano de, Dienstmann,Guilherme, Nascimento,Iramar Baptistella do, Silva,Jean Carl
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista brasileira de ginecologia e obstetrícia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032019001200697
Resumo: Abstract Objective To evaluate the factors associated with the need for insulin as a complementary treatment to metformin in pregnant women with gestational diabetes mellitus (GDM). Methods A case-control study was performed from April 2011 to February 2016 with pregnant women with GDM who needed complementary treatments besides diet and physical exercise. Those treated with metformin were compared with those who, in addition to metformin, also needed the combination with insulin. Maternal characteristics and glycemic control were evaluated. Multinomial logistic regression models were developed to evaluate the influence of different therapies on neonatal outcomes. Results A total of 475 pregnant women who needed pharmacological therapy were evaluated. Of these, 366 (77.05%) were submitted to single therapy with metformin, and 109 (22.94%) needed insulin as a complementary treatment. In the analysis of the odds ratio (OR), fasting glucose (FG)<90 mg/dL reduced the odds of needing the combination (OR: 0.438 [0.235-0.815]; p=0.009], as well as primiparity (OR: 0.280 [0.111-0.704]; p=0.007]. In obese pregnant women, an increased chance of needing the combination was observed (OR: 2,072 [1,063-4,039]; p=0,032). Conclusion Obesity resulted in an increased chance of the mother needing insulin as a complementary treatment to metformin, while FG<90 mg/dL and primiparity were protective factors.
id FEBRASGO-1_500243397bbe177261211c71a3c8265a
oai_identifier_str oai:scielo:S0100-72032019001200697
network_acronym_str FEBRASGO-1
network_name_str Revista brasileira de ginecologia e obstetrícia (Online)
repository_id_str
spelling Factors Associated with the Need for Insulin as a Complementary Treatment to Metformin in Gestational Diabetes Mellitusgestational diabetesmetformininsulincombined treatmentAbstract Objective To evaluate the factors associated with the need for insulin as a complementary treatment to metformin in pregnant women with gestational diabetes mellitus (GDM). Methods A case-control study was performed from April 2011 to February 2016 with pregnant women with GDM who needed complementary treatments besides diet and physical exercise. Those treated with metformin were compared with those who, in addition to metformin, also needed the combination with insulin. Maternal characteristics and glycemic control were evaluated. Multinomial logistic regression models were developed to evaluate the influence of different therapies on neonatal outcomes. Results A total of 475 pregnant women who needed pharmacological therapy were evaluated. Of these, 366 (77.05%) were submitted to single therapy with metformin, and 109 (22.94%) needed insulin as a complementary treatment. In the analysis of the odds ratio (OR), fasting glucose (FG)<90 mg/dL reduced the odds of needing the combination (OR: 0.438 [0.235-0.815]; p=0.009], as well as primiparity (OR: 0.280 [0.111-0.704]; p=0.007]. In obese pregnant women, an increased chance of needing the combination was observed (OR: 2,072 [1,063-4,039]; p=0,032). Conclusion Obesity resulted in an increased chance of the mother needing insulin as a complementary treatment to metformin, while FG<90 mg/dL and primiparity were protective factors.Federação Brasileira das Sociedades de Ginecologia e Obstetrícia2019-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032019001200697Revista Brasileira de Ginecologia e Obstetrícia v.41 n.12 2019reponame:Revista brasileira de ginecologia e obstetrícia (Online)instname:Federação Brasileira das Sociedades de Ginecologia e Obstetrícia (FEBRASGO)instacron:FEBRASGO10.1055/s-0039-1700796info:eu-repo/semantics/openAccessSouza,Matheus Leite Ramos deSilva,Rodrigo Ribeiro eSilva,Thiago Ribeiro eOliveira,Larissa Cano deDienstmann,GuilhermeNascimento,Iramar Baptistella doSilva,Jean Carleng2020-01-29T00:00:00Zoai:scielo:S0100-72032019001200697Revistahttp://www.scielo.br/rbgohttps://old.scielo.br/oai/scielo-oai.phppublicações@febrasgo.org.br||rbgo@fmrp.usp.br1806-93390100-7203opendoar:2020-01-29T00:00Revista brasileira de ginecologia e obstetrícia (Online) - Federação Brasileira das Sociedades de Ginecologia e Obstetrícia (FEBRASGO)false
dc.title.none.fl_str_mv Factors Associated with the Need for Insulin as a Complementary Treatment to Metformin in Gestational Diabetes Mellitus
title Factors Associated with the Need for Insulin as a Complementary Treatment to Metformin in Gestational Diabetes Mellitus
spellingShingle Factors Associated with the Need for Insulin as a Complementary Treatment to Metformin in Gestational Diabetes Mellitus
Souza,Matheus Leite Ramos de
gestational diabetes
metformin
insulin
combined treatment
title_short Factors Associated with the Need for Insulin as a Complementary Treatment to Metformin in Gestational Diabetes Mellitus
title_full Factors Associated with the Need for Insulin as a Complementary Treatment to Metformin in Gestational Diabetes Mellitus
title_fullStr Factors Associated with the Need for Insulin as a Complementary Treatment to Metformin in Gestational Diabetes Mellitus
title_full_unstemmed Factors Associated with the Need for Insulin as a Complementary Treatment to Metformin in Gestational Diabetes Mellitus
title_sort Factors Associated with the Need for Insulin as a Complementary Treatment to Metformin in Gestational Diabetes Mellitus
author Souza,Matheus Leite Ramos de
author_facet Souza,Matheus Leite Ramos de
Silva,Rodrigo Ribeiro e
Silva,Thiago Ribeiro e
Oliveira,Larissa Cano de
Dienstmann,Guilherme
Nascimento,Iramar Baptistella do
Silva,Jean Carl
author_role author
author2 Silva,Rodrigo Ribeiro e
Silva,Thiago Ribeiro e
Oliveira,Larissa Cano de
Dienstmann,Guilherme
Nascimento,Iramar Baptistella do
Silva,Jean Carl
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Souza,Matheus Leite Ramos de
Silva,Rodrigo Ribeiro e
Silva,Thiago Ribeiro e
Oliveira,Larissa Cano de
Dienstmann,Guilherme
Nascimento,Iramar Baptistella do
Silva,Jean Carl
dc.subject.por.fl_str_mv gestational diabetes
metformin
insulin
combined treatment
topic gestational diabetes
metformin
insulin
combined treatment
description Abstract Objective To evaluate the factors associated with the need for insulin as a complementary treatment to metformin in pregnant women with gestational diabetes mellitus (GDM). Methods A case-control study was performed from April 2011 to February 2016 with pregnant women with GDM who needed complementary treatments besides diet and physical exercise. Those treated with metformin were compared with those who, in addition to metformin, also needed the combination with insulin. Maternal characteristics and glycemic control were evaluated. Multinomial logistic regression models were developed to evaluate the influence of different therapies on neonatal outcomes. Results A total of 475 pregnant women who needed pharmacological therapy were evaluated. Of these, 366 (77.05%) were submitted to single therapy with metformin, and 109 (22.94%) needed insulin as a complementary treatment. In the analysis of the odds ratio (OR), fasting glucose (FG)<90 mg/dL reduced the odds of needing the combination (OR: 0.438 [0.235-0.815]; p=0.009], as well as primiparity (OR: 0.280 [0.111-0.704]; p=0.007]. In obese pregnant women, an increased chance of needing the combination was observed (OR: 2,072 [1,063-4,039]; p=0,032). Conclusion Obesity resulted in an increased chance of the mother needing insulin as a complementary treatment to metformin, while FG<90 mg/dL and primiparity were protective factors.
publishDate 2019
dc.date.none.fl_str_mv 2019-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032019001200697
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032019001200697
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1055/s-0039-1700796
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Federação Brasileira das Sociedades de Ginecologia e Obstetrícia
publisher.none.fl_str_mv Federação Brasileira das Sociedades de Ginecologia e Obstetrícia
dc.source.none.fl_str_mv Revista Brasileira de Ginecologia e Obstetrícia v.41 n.12 2019
reponame:Revista brasileira de ginecologia e obstetrícia (Online)
instname:Federação Brasileira das Sociedades de Ginecologia e Obstetrícia (FEBRASGO)
instacron:FEBRASGO
instname_str Federação Brasileira das Sociedades de Ginecologia e Obstetrícia (FEBRASGO)
instacron_str FEBRASGO
institution FEBRASGO
reponame_str Revista brasileira de ginecologia e obstetrícia (Online)
collection Revista brasileira de ginecologia e obstetrícia (Online)
repository.name.fl_str_mv Revista brasileira de ginecologia e obstetrícia (Online) - Federação Brasileira das Sociedades de Ginecologia e Obstetrícia (FEBRASGO)
repository.mail.fl_str_mv publicações@febrasgo.org.br||rbgo@fmrp.usp.br
_version_ 1754115944953675776